Somewhat Positive Media Coverage Somewhat Unlikely to Affect Edwards Lifesciences Corp (EW) Share Price
Media headlines about Edwards Lifesciences Corp (NYSE:EW) have been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Edwards Lifesciences Corp earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news articles about the medical research company an impact score of 45.562581984908 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news headlines that may have impacted Accern’s scoring:
- Active Stocks on Watch: Edwards Lifesciences Corp (EW) and Salesforce.com Inc (CRM) – Evergreen Caller (evergreencaller.com)
- Dissecting the Numbers for Edwards Lifesciences Corporation (EW) and Stryker Corporation (SYK) – StockNewsGazette (stocknewsgazette.com)
- Here's Why You Should Buy Lantheus Holdings (LNTH) Right Now (finance.yahoo.com)
- Thermo Fisher Acquires Patheon, Boosts Laboratory Products (finance.yahoo.com)
- Donald E. Bobo, Jr. Sells 5,300 Shares of Edwards Lifesciences Corp (EW) Stock (americanbankingnews.com)
A number of analysts have recently commented on EW shares. Zacks Investment Research lowered Edwards Lifesciences Corp from a “buy” rating to a “hold” rating in a report on Thursday, May 18th. BidaskClub lowered Edwards Lifesciences Corp from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Bank of America Corporation upped their target price on Edwards Lifesciences Corp from $140.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, July 27th. SunTrust Banks, Inc. upped their target price on Edwards Lifesciences Corp to $14.00 and gave the stock a “buy” rating in a report on Monday, July 17th. Finally, Goldman Sachs Group, Inc. (The) began coverage on Edwards Lifesciences Corp in a report on Tuesday, May 16th. They set a “conviction-buy” rating and a $138.00 target price on the stock. Six analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $120.18.
Edwards Lifesciences Corp (NYSE:EW) opened at 112.69 on Thursday. The company has a market capitalization of $23.80 billion, a PE ratio of 34.18 and a beta of 0.63. Edwards Lifesciences Corp has a 52 week low of $81.12 and a 52 week high of $121.75. The stock has a 50 day moving average price of $115.76 and a 200-day moving average price of $106.74.
Edwards Lifesciences Corp (NYSE:EW) last posted its earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corp had a net margin of 22.11% and a return on equity of 26.27%. The company had revenue of $842 million during the quarter, compared to analysts’ expectations of $839.16 million. During the same period last year, the company posted $0.76 earnings per share. Edwards Lifesciences Corp’s quarterly revenue was up 10.9% on a year-over-year basis. On average, equities analysts predict that Edwards Lifesciences Corp will post $3.78 earnings per share for the current fiscal year.
In other Edwards Lifesciences Corp news, VP Donald E. Bobo, Jr. sold 5,600 shares of the business’s stock in a transaction that occurred on Thursday, June 29th. The shares were sold at an average price of $117.15, for a total transaction of $656,040.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Michael A. Mussallem sold 32,900 shares of the business’s stock in a transaction that occurred on Wednesday, June 7th. The stock was sold at an average price of $118.05, for a total transaction of $3,883,845.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 163,541 shares of company stock valued at $18,896,959. Company insiders own 2.13% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was first posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.watchlistnews.com/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-edwards-lifesciences-corp-ew-share-price/1532796.html.
About Edwards Lifesciences Corp
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.